AEON Biopharma, Inc. Cash Flow Conversion Efficiency
AEON Biopharma, Inc. cash flow conversion efficiency. Based on the latest financial reports, AEON Biopharma, Inc. (AEON) has a cash flow conversion efficiency ratio of 0.131x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.60 Million) by net assets ($-19.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of AEON Biopharma, Inc. (2019–2024)
Cash flow conversion efficiency of AEON Biopharma, Inc. from 2019 to 2024. This chart illustrates how AEON Biopharma, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View AEON live share price for real-time trading data and today's change.
AEON Biopharma, Inc. Cash Flow Conversion Ratio Explained
AEON Biopharma, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
AEON Biopharma, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AEON Biopharma, Inc. ranked by their cash flow conversion efficiency. Also see AEON stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VerifyMe Inc
NASDAQ:VRME
|
0.005x |
|
MILA RESOUR. PLC LS-01
F:HN0
|
N/A |
|
SaveLend Group AB
ST:YIELD
|
0.019x |
|
Clean Air Metals Inc
V:AIR
|
-0.013x |
|
Yonga Mobilya Sanayi ve Ticaret AS
IS:YONGA
|
-0.317x |
|
Flexidynamic Holdings Bhd
KLSE:0231
|
0.121x |
|
Aban Offshore Limited
NSE:ABAN
|
0.002x |
|
Target Healthcare REIT Ltd
LSE:THRL
|
0.033x |
Annual Cash Flow Conversion Efficiency for AEON Biopharma, Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of AEON Biopharma, Inc. from 2019 to 2024. Review AEON Biopharma, Inc. leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-28.57 Million | $-20.29 Million | 0.710x | +127.30% |
| 2023-12-31 | $-153.04 Million | $-47.83 Million | 0.312x | +137.47% |
| 2022-12-31 | $-270.41 Million | $-35.58 Million | 0.132x | +3.59% |
| 2021-12-31 | $-223.82 Million | $-28.43 Million | 0.127x | +172.88% |
| 2020-12-31 | $-203.23 Million | $-9.46 Million | 0.047x | -93.14% |
| 2019-12-31 | $-65.87 Million | $-44.73 Million | 0.679x | -- |
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of ga… Read more